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Subchronic treatment with the psychotomimetic phencyclidine (PCP) has been proposed as a 
rodent model of the negative and cognitive/executive symptoms of schizophrenia. There has, 
however, been a paucity of studies on this model in mice, despite the growing use of the mouse as 
a subject in genetic and molecular studies of schizophrenia. In the present study, we evaluated the 
effects of subchronic PCP treatment (5 mg/kg twice daily × 7 days, followed by 7 days withdrawal) 
in C57BL/6J mice on (1) social behaviors using a sociability/social novelty-preference paradigm, 
and (2) pairwise visual discrimination and reversal learning using a touchscreen-based operant 
system. Results showed that mice subchronically treated with PCP made more visits to (but did 
not spend more time with) a social stimulus relative to an inanimate one, and made more visits 
and spent more time investigating a novel social stimulus over a familiar one. Subchronic PCP 
treatment did not signiﬁ  cantly affect behavior in either the discrimination or reversal learning 
tasks. These data encourage further analysis of the potential utility of mouse subchronic PCP 
treatment for modeling the social withdrawal component of schizophrenia. They also indicate 
that the treatment regimen employed was insufﬁ  cient to impair our measures of discrimination 
and reversal learning in the C57BL/6J strain. Further work will be needed to identify alternative 
methods (e.g., repeated cycles of subchronic PCP treatment, use of different mouse strains) that 
reliably produce discrimination and/or reversal impairment, as well as other cognitive/executive 
measures that are sensitive to chronic PCP treatment in mice.
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hyperactivity that is reversible by antipsychotics. This drug response 
has been proposed as a measure relevant to positive symptoms in 
schizophrenia, and has been extensively studied as such (Arguello 
and Gogos, 2006; Powell and Miyakawa, 2006).
There is increasing recognition that the negative and cognitive/
executive symptoms of schizophrenia are inadequately treated and 
underrepresented in rodent models of the disease (Carter et al., 
2008). In this context, repeated (‘subchronic’) treatment with PCP 
has been found to produce a range of persistent behavioral distur-
bances in non-human primates, rats and mice, that may model 
some of these symptoms (Jentsch and Roth, 1999). For example, 
previous studies have demonstrated that following subchronic 
PCP treatment, rats display impairments in T-maze spatial work-
ing memory (Jentsch and Taylor, 2001; Jentsch et al., 1997b) (but 
see Stefani and Moghaddam, 2002), T-maze spatial reversal learn-
ing (Jentsch and Taylor, 2001), extra-dimensional set-shifting 
(EDS; Egerton et al., 2008; Rodefer et al., 2005, 2008), and reversal 
learning in maze- and operant-based tasks (Abdul-Monim et al., 
2006, 2007; Jentsch and Taylor, 2001). Although there have been 
fewer reports on subchronic PCP effects in mice, one recent study 
observed deﬁ  cits in reversal learning and EDS in the C57BL/6J 
inbred mouse strain (Laurent and Podhorna, 2004), while another 
INTRODUCTION
Schizophrenia is a heterogeneous disease characterized by posi-
tive, negative and cognitive/executive symptoms (DSM-IV, 1994). 
Positive symptoms (so-called because they add to the normal 
behavioral repertoire) include hallucinations, psychomotor agita-
tion and hypersensitivity to psychotomimetics. Amongst the nega-
tive symptoms (so-called because they subtract from the normal 
behavioral repertoire) are blunted affect, anhedonia and low moti-
vation, and social withdrawal. The cognitive/executive symptom 
category encompasses a range of deﬁ  cits including impaired dis-
crimination learning and reversal learning (Murray et al., 2008) 
and attentional set-shifting problem (Braff et al., 1991).
Drugs with N-methyl-D-aspartate receptor (NMDAR) antago-
nist properties, such as ketamine and phencyclidine (PCP), mimic 
the symptoms of schizophrenia in healthy human subjects and 
cause relapse in schizophrenics (Adler et al., 1999; Krystal et al., 
1994; Malhotra et al., 1997; Newcomer et al., 1999). In rodents, 
treatment with NMDAR antagonists also produce various behav-
ioral abnormalities posited to be relevant to positive symptoms of 
schizophrenia (Arguello and Gogos, 2006; Powell and Miyakawa, 
2006). For example, acute administration of the NMDAR antago-
nists PCP or MK-801 (dizocilpine) produces a profound locomotor 
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found no impairment in radial arm maze working memory in the 
same strain (Li et al., 2003).
Previous studies have shown that subchronic PCP treatment 
also models social withdrawal component of schizophrenia, in that 
rats having undergone this treatment show reduced social inter-
action with a conspeciﬁ  c in a dyadic encounter (Lee et al., 2005; 
Sams-Dodd, 1995; Schwabe et al., 2006; Snigdha and Neill, 2008a,b; 
Tanaka et al., 2003) (but see Egerton et al., 2008). However, there 
have been fewer published data showing similar deﬁ  cits in social 
behavior of mice (Qiao et al., 2001; Wang et al., 2007).
The general paucity of literature on subchronic PCP effects 
on behavioral measures in mice related to both the social and 
  cognitive/executive symptoms of schizophrenia, contrasts with 
the growing use of the mouse as the subject of choice in genetic 
and molecular studies of the role of NMDARs and other compo-
nents of the glutamate system in the pathophysiology of schiz-
ophrenia (e.g., Karlsson et al., 2008, 2009; Labrie et al., 2008; 
Miyamoto et al., 2001; Mohn et al., 1999; Wiedholz et al., 2008) 
and frequently comorbid disorders such as anxiety and alcoholism 
(e.g., Boyce-Rustay and Holmes, 2005, 2006; Crabbe et al., 2006; 
Cryan and Dev, 2007; Palachick et al., 2008). A better understand-
ing of the potential effects of subchronic PCP on these behav-
iors would facilitate the comparison and convergence of mouse 
NMDAR-related pharmacological and gene mutant models of 
schizophrenia.
In the present study we tested for persistent effects of subchronic 
PCP treatment in C57BL/6J mice on social behaviors, using a task 
recently shown to be valuable in the study of social abnormalities 
in mouse models of neurodevelopmental disorders such as autism 
(Crawley, 2004). In addition, we tested for subchronic PCP effects 
on pairwise visual discrimination and reversal learning using a 
mouse touchscreen-based operant system (Brigman et al., 2005; 
Izquierdo et al., 2006; Morton et al., 2006).
MATERIALS AND METHODS
SUBJECTS
Subjects were male C57BL/6J obtained from The Jackson Laboratory 
(Bar Harbor, ME, USA) at 2 months of age and tested/treated begin-
ning at 2–5 months of age. The C57BL/6J strain was selected on the 
basis of its frequent use in behavioral neuroscience and as a genetic 
background for mutant models of schizophrenia, as well as its inclu-
sion as a “group A” priority strain in the Mouse Phenome Project, an 
international effort to provide the biomedical research community 
with phenotypic data on the most commonly used mouse strains 
(www.jax.org/phenome). Mice were housed two per cage in a tem-
perature- (72 ± 5°C) and humidity- (45 ± 15%) controlled vivarium 
under a 12-h light/dark cycle (lights on 0600 h). The number of mice 
used is given in the ﬁ  gure legends. All experimental procedures were 
approved by the National Institute on Alcohol Abuse and Alcoholism 
Animal Care and Use Committee and followed the National Institute 
of Health guidelines outlined in ‘Using Animals in Intramural 
Research’ and the local Animal Care and Use Committees.
SUBCHRONIC PCP TREATMENT
Mice were intraperitoneally injected with 5 mg/kg PCP (Sigma-
Aldrich, St Louis, MO, USA) or saline vehicle (in a volume of 
10  mL/kg body weight) twice daily (morning and evening, 
  separated by 12 h) for 7 consecutive days. Fresh solutions were 
  prepared daily. To facilitate the comparison of drug effects on 
the social and reversal tasks, mice used in these experiments were 
treated at the same time using the same drug solutions. Testing 
was conducted (for social) or began (for operant) 7 days after the 
ﬁ  nal PCP treatment. One cohort of mice was tested for socia-
bility and social novelty preference. A separate cohort of was 
trained  through pre-training criterion then treated with PCP 
and tested for discrimination 7 days later. A third cohort of mice 
was trained through discrimination criterion then treated with 
PCP and tested for reversal 7 days later. The dose and treatment/
withdrawal procedure employed was based on a previous study 
demonstrating that the same procedure impaired reversal learning 
in rats (Jentsch and Taylor, 2001).
SOCIABILITY AND SOCIAL NOVELTY PREFERENCE
The effects of subchronic PCP treatment on social behavior 
were assessed based on methods previously described to test for 
autism- and schizophrenia-related phenotypes in mice (Crawley, 
2007; McFarlane et al., 2008). The apparatus was a white Plexiglas 
square arena (40  cm  × 40 cm × 35 cm,  25 lux)  containing  two 
wire-bar cups (Galaxy Cup, Spectrum Diversiﬁ  ed Designs, Inc., 
Streetsboro, OH, USA) placed on either side of the arena. Plastic 
cups were placed over the wire-bar cups to prevent the subject 
from climbing on top. The mouse was initially habituated to the 
arena for 20 min, during which time two black Plexiglas (38 cm × 
13.5 cm × 14 cm) boxes completely covered the sides of the arena 
containing the cups.
The mouse was initially habituated to the arena for 20 min, dur-
ing which time it was prevented from entering the sides of the arena 
containing the cups by the insertion of black Plexiglas partitions.
Sociability
The Plexiglas partitions were removed and an unfamiliar male 
C57BL/6J mouse was placed in one wire-bar cup (social stimu-
lus). The other wire-bar cup remained empty (inanimate stimulus). 
The test mouse was manually observed for the total duration of 
investigation (deﬁ  ned as snout in physical contact with the wire-bar 
cup) and the cumulative number of investigations (a discrete inves-
tigation was scored when the snout was continuously in contact 
with the cup and until the snout was turned away from the cup) of 
the social and inanimate stimuli, and transitions between stimuli, 
over a 10-min test session using the Hindsight software program 
(Scientiﬁ  c Programming Services, Wokingham, UK).
Social novelty preference
Immediately after the sociability test, the inanimate stimulus was 
replaced with another unfamiliar male C57BL/6J mouse such that 
the test mouse now had a choice between investigating the now-
familiar social stimulus vs. the novel social stimulus. Stimuli inves-
tigation and inter-stimuli transitions were measured as above over 
a 10-min test session.
Analysis of sociability and social novelty preference data
Consistent with earlier reports (e.g., McFarlane et al., 2008) we 
did not consider drug treatment and stimulus-type as independ-
ent factors and analyze by use of analysis of variance. Instead, the Frontiers in Behavioral Neuroscience  www.frontiersin.org  February  2009 | Volume  3 | Article  2 | 3
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effects of stimulus-type on dependent measures in the sociability 
and social novelty preference tests were analyzed within each treat-
ment group by use of paired t-tests with Bonferroni correction for 
multiple comparisons. Drug treatment groups were compared for 
transitions between stimuli by unpaired t-test.
PAIRWISE DISCRIMINATION LEARNING AND REVERSAL
The effects of subchronic PCP treatment on pairwise visual dis-
crimination learning and reversal using a murine touchscreen-
based operant system, as previously described (Brigman et al., 
2008; Izquierdo et al., 2006).
Apparatus
An operant chamber measuring 21.6  cm  × 17.8 cm × 12.7 cm 
(model # ENV-307W, Med Associates, St Albans, VT, USA) was 
housed within a sound and light attenuating box (Med Associates). 
The grid ﬂ  oor of the chamber was covered with solid Plexiglas to 
facilitate ambulation. A pellet dispenser delivering 14 mg dustless 
pellets (#F05684, BioServ, Frenchtown, NJ, USA) into a magazine 
located at one end of the chamber. At the opposite end of the cham-
ber there was a touch-sensitive screen (Light Industrial Metal Cased 
TFT LCD Monitor, Craft Data Limited, Chesham, UK), a house-
light, and a tone generator. The touchscreen was covered by a black 
Plexiglas panel that had 2 cm × 5 cm windows separated by 0.5 cm 
and located at a height of 6.5 cm from the ﬂ  oor of the chamber. 
Stimuli presented on the screen were controlled by custom software 
(‘MouseCat’, L.M. Saksida) and were visible through the windows 
(one stimulus/window). Nosepokes at the stimuli were detected by 
the touchscreen and recorded by the software.
Autoshaping and instrumental pre-training
Mice were slowly reduced and then maintained at 85% free-feeding 
body weight. Prior to testing, mice were acclimated to the 14 mg 
pellet food reward by provision of ∼10 pellets/mouse in the home 
cage for 1–3 days. Mice were then acclimated to the operant cham-
ber and to eating out of the pellet magazine by being placed in 
the chamber for 30 min with pellets available in the magazine. 
Mice eating 10 pellets within 30 min were moved onto autoshap-
ing. During autoshaping variously shaped stimuli were presented 
in the touchscreen windows (one per window) for 10 s [inter-trial 
interval (ITI) 15 s]. The disappearance of the stimuli coincided 
with provision of a single pellet food reward, concomitant with 
presentation of stimuli (2-s 65 dB auditory tone and illumination 
of pellet magazine) that served to support instrumental learning. 
Retrieval of the pellet from the pellet magazine (detected as a head 
entry) triggered the next trial. To encourage screen approaches and 
touches at this stage, nosepokes at the touchscreen delivered three 
pellets in the magazine.
Mice retrieving 30 pellets within 30  min were moved onto 
pre-training. During pre-training mice ﬁ  rst obtained rewards by 
responding to a (variously-shaped) stimulus that appeared in one 
of the two windows (spatially pseudorandomized) and remained on 
the screen until a response was made (‘respond’ phase). Mice retriev-
ing 30 pellets within 30 min were next required to initiate each new 
trial with a head entry into the pellet magazine (‘respond’ phase). In 
addition, responses at a blank window during stimulus presentation 
produced a 5 s timeout (signaled by extinction of the house light) 
to discourage indiscriminate screen responding   (‘punish’ phase). 
Incorrect responses were followed by correction trials in which the 
same stimulus and spatial conﬁ  guration was presented until a cor-
rect response was made. Mice making ≥75% (excluding correction 
trials) of their responses at a stimulus-containing window over a 
30-trial session were moved onto discrimination.
Discrimination
Two novel approximately equiluminescent stimuli were presented 
in spatially pseudorandomized manner over 30-trial sessions 
(15 s ITI). Responses at one stimulus (correct) resulted in reward; 
responses at the other stimulus (incorrect) resulted in a 5 s time-
out (signaled by extinction of the house light) and were followed 
by a correction trial. Stimuli remained on screen until a response 
was made. Designation of the correct and incorrect stimulus was 
counterbalanced across drug treatment. Performance criterion was 
performing at an average of 85% correct (excluding correction 
trials) over two consecutive sessions.
Reversal
The session after attaining discrimination criterion, the designa-
tion of stimuli as correct vs. incorrect was reversed for each mouse 
and performance tested over 30-trial daily sessions to a criterion 
of 85% correct (excluding correction trials) on each of 2 consecu-
tive days.
Operant data analysis
The dependent variable measured during autoshaping and pre-
 training was trials to criterion on each phase. The dependent variables 
measured during discrimination and reversal were trials, errors and 
correction errors to criterion, and average reaction time and reward 
retrieval latency. To further examine perseverative responding during 
reversal, we calculated a perseveration index (=average number of 
correction errors committed per error committed) (Brigman et al., 
2008). The effect of drug treatment on these measures was analyzed 
using Student’s t-test. Finally, to test whether drug treatment effects 
were restricted to the early phases of the discrimination and reversal 
tasks (and potentially diluted in the to-criterion measures), we exam-
ined percent correct performance during the ﬁ  rst ﬁ  ve sessions on 
each task using two-factor drug treatment × session ANOVAs.
RESULTS
SOCIABILITY AND SOCIAL NOVELTY PREFERENCE
Sociability
Saline-treated mice spent signiﬁ  cantly more time with the social 
than inanimate stimulus (t = 6.04, df = 7, p < 0.001) whereas PCP-
treated mice showed trend in the same direction that was not statis-
tically signiﬁ  cant (t = 2.71, df = 6, p = 0.035, non-signiﬁ  cant after 
Bonferroni correction) (Figure 1A). Both saline-treated (t = 8.56, 
df = 7, p < 0.001) and PCP-treated (t = 4.00, df = 6, p = 0.007) mice 
made signiﬁ  cantly more visits to the social than the inanimate stim-
ulus (Figure 1B). Saline-treated mice were signiﬁ  cantly quicker to 
ﬁ  rst investigate the social than inanimate stimulus (t = 3.15, df = 7, 
p = 0.016) whereas PCP-treated mice (t = 1.79, df = 6, p = 0.124) 
were not (Figure 1C). The number of transitions between the social 
and inanimate stimuli did not differ between saline- and PCP-
treated mice (t = 0.80, df = 13, p = 0.439) (Figure 1D).Frontiers in Behavioral Neuroscience  www.frontiersin.org  February  2009 | Volume  3 | Article  2 | 4
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Social novelty preference
Saline-treated (t = 5.83, df = 7, p < 0.001) and PCP-treated (t = 5.59, 
df = 6, p = 0.001) mice spent signiﬁ  cantly more time with the novel 
than the familiar social stimulus (Figure 2A). Both saline-treated 
(t = 4.89,  df = 7,  p = 0.002)  and  PCP-treated  (t = 4.24,  df = 6, 
p = 0.006) mice also made signiﬁ  cantly more visits to the novel 
than the familiar social stimulus (Figure 2B). Neither saline-treated 
(t = 1.53,  df = 7,  p = 0.169)  nor  PCP-treated  (t = 1.80,  df = 6, 
p = 0.122) mice were signiﬁ  cantly quicker to ﬁ  rst investigate the 
novel than the familiar social stimulus (Figure 2C). The number of 
transitions between the social and inanimate stimuli did not differ 
between saline- and PCP-treated mice (t = 2.07, df = 13, p = 0.059) 
(Figure 2D).
PAIRWISE DISCRIMINATION LEARNING AND REVERSAL
Discrimination learning
Prior to drug treatment, saline and PCP groups did not signiﬁ  -
cantly differ in the number of sessions taken to attain autoshaping 
or pre-training criteria (Table 1). Following treatment, there was 
no signiﬁ  cant effect of PCP treatment on the number of trials, 
errors or correction errors committed to attain discrimination 
criterion (Figures 3A–C). Stimulus reaction time and reward 
retrieval latency were also no different between treatment groups 
(Figures 3D,E). Examination of the ﬁ  rst ﬁ  ve discrimination ses-
sions found a signiﬁ  cant effect of session (F4,48 = 8.17, p < 0.01) 
but not drug treatment and no session × treatment interaction 
(Table 2).
Reversal
Prior to drug treatment, saline and PCP groups did not signiﬁ  cantly 
differ in the number of sessions taken to attain autoshaping or pre-
training criteria, or in the number of trials, errors or correction 
errors committed in reaching discrimination criterion (Table 1). 
Following treatment, there was no signiﬁ  cant effect of PCP treat-
ment on the number of trials, errors or correction errors com-
mitted to attain reversal criterion (Figures 4A–C). Perseveration 
index, stimulus reaction time and reward retrieval latency were 
also no different between treatment groups (Figures 4D–F). 
Examination of the ﬁ  rst ﬁ  ve reversal sessions found a signiﬁ  cant 
effect of session (F4,48 = 16.05, p < 0.01) but not drug treatment 
and no session × treatment interaction (Table 2). (Note: one saline-
treated mouse failed to reach criterion after being offered 900 trials 
was excluded from the analysis).
DISCUSSION
The results of the current study showed that subchronic PCP 
  treatment did not affect either pairwise discrimination or reversal 
learning in C57BL/6J mice. The same treatment did, however, pro-
duce preliminary evidence of a partial decrease in social behavior.
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FIGURE 1 | Effects of subchronic PCP treatment on sociability in C57BL/6J 
mice. In contrast to saline-treated controls, mice subchronically treated with 
PCP did not spend signiﬁ  cantly more time investigating the social stimulus than 
the inanimate stimulus (A). Mice subchronically treated with either PCP or saline 
made signiﬁ  cantly more investigations of the social stimulus than the inanimate 
stimulus (B). Saline but not PCP-treated mice were signiﬁ  cantly faster to ﬁ  rst 
investigate the social stimulus than the inanimate stimulus (C). Treatment did 
not affect the number of transitions between stimuli (D). Inamin = inanimate 
stimulus. Data are mean ± SEM. n = 7–8 per treatment. #p < 0.05 vs. inanimate/
same treatment group.Frontiers in Behavioral Neuroscience  www.frontiersin.org  February  2009 | Volume  3 | Article  2 | 5
Brigman et al.  Subchronic PCP in mice
75
#
60
45
D
u
r
a
t
i
o
n
 
o
f
 
s
t
i
m
u
l
u
s
i
n
v
e
s
t
i
g
a
t
i
o
n
 
(
s
e
c
)
AB
CD
30
15
0
Inanim Social
Saline PCP
Inanim Social
30
#
#
25
20
N
u
m
b
e
r
 
o
f
 
s
t
i
m
u
l
u
s
i
n
v
e
s
t
i
g
a
t
i
o
n
s
15
10
5
0
Inanim Social
Saline PCP
Inanim Social
125
100
75
L
a
t
e
n
c
y
 
t
o
 
f
i
r
s
t
s
t
i
m
u
l
u
s
 
v
i
s
i
t
50
25
0
Inanim Social
Saline PCP
Inanim Social
30
25
20
I
n
t
e
r
-
s
t
i
m
u
l
u
s
t
r
a
n
s
i
t
i
o
n
s
15
10
5
0
Saline PCP
FIGURE 2 | Effects of subchronic PCP treatment on social novelty preference 
in C57BL/6J mice. Mice subchronically treated with either PCP or saline spent 
signiﬁ  cantly more time investigating (A) and made signiﬁ  cantly more investigations 
of (B) the novel social stimulus than the familiar social stimulus. Neither treatment 
group showed a signiﬁ  cant difference in latency to ﬁ  rst visit the novel social 
stimulus than the familiar social stimulus (C). Treatment did not affect the number 
of transitions between stimuli (D). n = 7–8 per treatment. Inamin = inanimate 
stimulus. Data are mean ± SEM. #p < 0.05 vs. familiar/same treatment group.
Table 1 | Instrumental performance prior to PCP treatment. There were no differences in performance between treatment groups prior to treatment in 
either the discrimination or reversal experiments. Data are mean ± SEM units to criterion, except for stimulus reaction time and reward retrieval latency with 
are seconds.
  Pre-discrimination experiment  Pre-reversal experiment
 Saline  PCP  Saline  PCP
Autoshaping 1.0  ± 0.0  1.0 ± 0.0  1.0 ± 0.0  1.0 ± 0.0
PRE-TRAINING
Respond phase  2.8 ± 0.2  2.4 ± 0.2  2.0 ± 0.2  2.3 ± 0.2
Punish phase  2.6 ± 0.4  2.2 ± 0.5  1.8 ± 0.5  2.4 ± 0.6
DISCRIMINATION
Trials –  –  210.3  ± 31.1  233.6 ± 17 .7
Errors –  –  62.3  ±  18.1  66.0 ± 7. 4
Correction errors  –  –  197 .3 ± 17 .4  133.9 ± 13.5
Stimulus reaction time  –  –  2.1 ± 0.3  1.6 ± 0.1
Reward retrieval latency  –  –  4.8 ± 0.3  4.3 ± 3.1
The sociability/social novelty preference paradigm we employed 
to test for PCP-induced social withdrawal has been proposed 
(Crawley, 2004) and proven valuable (Jamain et al., 2008; McFarlane 
et al., 2008; Moy et al., 2009) as a test for social deﬁ  cits in mouse 
models of autism spectrum disorders. Extending these ﬁ  ndings, we 
examined social behaviors in the task following subchronic PCP 
treatment in C57BL/6J mice. PCP-treated mice showed more visits 
to a social stimulus than an inanimate stimulus, but only showed a Frontiers in Behavioral Neuroscience  www.frontiersin.org  February  2009 | Volume  3 | Article  2 | 6
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trend for spending more time with the social stimulus, suggesting 
a partial attenuation of social preference in the drug treated mice. 
Underscoring the modest nature of the social deﬁ  cit, PCP-treated 
mice retained a preference for a novel social stimulus over a familiar 
social stimulus.
Importantly, given the known locomotor hyperactivity- inducing 
effects of PCP, assessment of social behaviors in PCP-treated mice was 
not associated with a non-speciﬁ  c change exploratory  locomotion, 
as measured by the number of transitions between stimuli (which 
were no different than saline controls). We have recently found that 
knockout mice lacking the glutamate transporter (GLAST), which 
display an antipsychotic-reversible ‘schizophrenia-like phenotype’ 
on measures related to the positive symptoms of the disease (i.e., 
novelty- and psychotomimetic-induced locomotor hyperactivity), 
also exhibit reduced social behaviors in this task (Karlsson et al., 
2009). Taken together with current ﬁ  ndings, these data suggest that 
the sociability/social novelty preference paradigm has some utility 
as a measure for social withdrawal in both pharmacological and 
gene mutant models of schizophrenia.
Previous work has show that various regimens of subchronic 
PCP treatment signiﬁ   cantly reduces social interaction during 
a dyadic encounter with an unfamiliar conspeciﬁ  c in rats (Lee 
et al., 2005; Sams-Dodd, 1995; Schwabe et al., 2006; Snigdha and 
Neill, 2008a,b; Tanaka et al., 2003) (but see Egerton et al., 2008) 
and (ICR or ddY strains of) mice (Qiao et al., 2001; Wang et al., 
2007). One distinguishing feature of the sociability/social novelty 
preference paradigm is that social interactions must be initiated 
and maintained by the test subject (Crawley, 2004). By contrast, in 
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Table 2 | Effects of subchronic PCP treatment on performance during early discrimination learning and reversal. PCP treatment has no signiﬁ  cant 
effect on percent correct performance during the ﬁ  rst ﬁ  ve sessions of either discrimination learning or reversal. Data are means ± SEM percent correct.
  Session #
  1  2 3 4 5
DISCRIMINATION
Saline-treated 53.8  ± 6.2  67 .6 ± 5.9  61.0 ± 8.3  58.1 ± 7 .9  70.0 ± 6.6
PCP-treated 51.7  ± 4.2  49.2 ± 7 .8  56.7 ± 9.1  63.3 ± 9.0  77 .5 ± 8.01
REVERSAL
Saline-treated 20.0  ± 6.1  26.1 ± 12.6  35.0 ±  11.0  35.6 ± 10.6  54.4 ± 10.0
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a ‘free’ dyadic social encounter, social behavior can be supported 
by both the subject and the stimulus. This difference could render 
the sociability/social novelty preference paradigm more sensitive 
to true-positive social deﬁ  cits in the subject mouse. Indeed, this 
has been borne out in recent examples in which putative mouse 
mutant models of autism (Jamain et al., 2008; McFarlane et al., 
2008) and schizophrenia (Karlsson et al., 2009) exhibited reduced 
social behavior in the sociability/social novelty preference test but 
not in a free dyadic social interaction test. It would be of inter-
est in future studies to directly compare the effects of subchronic 
PCP treatment on the sociability/social novelty preference and a 
free interaction test in C57BL/6J mice to determine whether the 
approaches differ in their sensitivity to this treatment. Testing under 
free social interaction would also allow for the measurement of 
alterations in aggression as a result of subchronic PCP treatment; 
which would be of interest given known effects of acute PCP on 
this behavior in mice (Miczek and Haney, 1994; Tyler and Miczek, 
1982; Wilmot et al., 1987).
Subchronic PCP treatment had no observable effects on 
either pairwise discrimination learning or reversal in a murine 
  touchscreen-based operant task previously shown to be sensitive 
to dopamine D1 agonist treatment in C57BL/6J mice,  as well as 
knockout of the NR2A NMDAR subunit (Brigman et al., 2008; 
Izquierdo et al., 2006). The negative effect of PCP was evidenced 
on multiple measures of performance that included trials and 
errors to discrimination criterion, and trials, errors, and correc-
tion errors to reversal criterion, as well as stimulus reaction time 
and reward retrieval latency in both tasks. Moreover, additional 
analysis of the ﬁ  rst ﬁ  ve sessions of the discrimination or reversal 
tasks also failed to uncover a drug effect. Thus, it appears unlikely 
that there was a subtle effect of treatment that our analysis was 
not able to detect.
While there are no directly comparable data from mouse or 
rat versions of this task, prior studies have examined subchronic 
PCP effects on discrimination and reversal in other experimental 
settings. For example, studies have tested PCP effects on discrimina-
tion and reversal as components within the intra-dimensional set-
shifting (IDS)/Extra-dimentional set-shifting (EDS) digging-based 
task developed by Birrell and Brown (Birrell and Brown, 2000) as 
an analogue of the Wisconsin Card Sorting Task in humans (Braff 
et al., 1991). Using the same subchronic PCP treatment regimen 
we used (albeit with a 10, rather than 7, day withdrawal period) 
Rodefer et al. (2005, 2008) found impaired EDS in rats, but no 
deﬁ  cits on either discrimination, reversal or IDS. A similar pattern 
of impairment restricted to EDS was recently observed by Egerton 
et al. (2008) in rats exposed to a somewhat milder PCP treatment 
regimen (5 days of once daily 2.6 mg/kg PCP and a 3-day with-
drawal period). The lack of effects on discrimination or reversal 
in these studies would be in line with our data.
There are, however, a number of examples of impairments in dis-
crimination and/or reversal following subchronic PCP treatment. 
One study found that C57BL/6J mice administered (1.3 mg/kg) 
PCP once daily for 5 days showed a general deﬁ  cit across com-
ponents of the Birrell and Brown task, including discrimination 
and reversal (Laurent and Podhorna, 2004). However, this general-
ized proﬁ  le of impairment may have resulted from PCP treatment 
2 h prior to testing, as acute PCP treatment is known to produce 
 deﬁ  cits, including impaired reversal, per se (Abdul-Monim et al., 
2003; Idris et al., 2005).
Perhaps more difﬁ  cult to reconcile with current negative data 
is a report of reversal (but not discrimination) impairment in rats 
given the same subchronic treatment as we used (Jentsch and Taylor, 
2001). The fact that their study differed from ours in a number of 
important methodological factors, such as the use of a T-maze- 
rather than an operant-based procedure, could account for the 
differences in ﬁ  ndings. However, there is also recent work by Neill 
and colleagues showing that the same regimen of treatment and 
withdrawal as we used (albeit with a lower, 2 mg/kg, dose) produced 
reversal (antipsychotic-reversible) deﬁ  cits on a rat operant task 
(Abdul-Monim et al., 2006, 2007). Again, variations in method-
ology could account for the difference. Of particular note, these 
authors employed a task similar in certain respects to a go/no-go 
procedure (i.e., subjects learned to respond for reward signaled by 
the presence or absence of a cue). This procedure likely placed a 
greater demand on inhibitory control than our task, which did not 
have the additional requirement that subjects inhibit responding 
on no-go. Thus, given evidence from Jentsch and colleagues that 
subchronic PCP treatment signiﬁ  cantly impairs inhibitory con-
trol in rats and non-human primates (Jentsch and Taylor, 2001; 
Jentsch et al., 1997a, 2000), this might have rendered their task more 
sensitive to the treatment than ours. Additional studies could test 
this hypothesis; e.g., by testing whether subchronic PCP impairs 
C57BL/6J mice on tasks in our touchscreen task that strongly tax 
inhibitory control, such as operant extinction (Hefner et al., 2008) 
and go/no-go. An alternative approach would be to modify our 
discrimination and reversal procedure to increase task difﬁ  culty; 
e.g., by increasing the perceptual similarity of the visual stimuli, 
presenting distracters or making reinforcement probabilistic.
Another interesting avenue for future work would be to deter-
mine regimens of PCP treatment that are sufﬁ  cient to impair the 
forms of discrimination and/or reversal tested in the current study; 
e.g., by increasing dose, treatment chronicity or the number of cycles 
of subchronic PCP treatment. Of note in this regard, chronic hos-
pitalized schizophrenic patients with frontal lobe damage have a 
profound impairment proﬁ  le that includes poor discrimination 
and reversal (Pantelis et al., 1999), while chronic stabilized patients 
are impaired on reversal and extra-dimensional shifts (Elliott et al., 
1995; Waltz and Gold, 2007), and ﬁ  rst-episode schizophrenics show 
milder proﬁ  le restricted to extra-dimensional impairment (Braw 
et al., 2008; Hutton et al., 1998; Joyce et al., 2002). These data could 
suggest that the severity of cognitive impairment on discrimination/
reversal/EDS in schizophrenia may be positively correlated with the 
chronicity of the disease (Joyce et al., 2002). Although arguing against 
this, however, are reports of reversal and extra-dimensional deﬁ  cits 
in ﬁ  rst-episode schizophrenics (Barnett et al., 2005; Murray et al., 
2008). Notwithstanding, these clinical data do raise the interesting 
question of whether discrimination and/or reversal deﬁ  cits in our 
task would become evident after more extensive PCP treatment.
While the main aim of the current study was to describe effects 
of subchronic PCP on measures of social behavior and cognitive/
executive function in mice, rather than elucidate the mechanisms 
underlying these effects, the observed dissociation between effects on 
these measures provided some initial clues into these mechanisms. 
PFC dysfunction in schizophrenia is thought to be a  principle locus Frontiers in Behavioral Neuroscience  www.frontiersin.org  February  2009 | Volume  3 | Article  2 | 9
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of the negative and cognitive/executive symptoms of the   disease 
(Tamminga, 2006; Tan et al., 2007). Subchronic PCP treatment 
has been shown to produce various long-lasting abnormalities in 
the rat PFC, including evidence of reduced dopamine utilization 
up to 3 weeks after the end of treatment (Jentsch et al., 1997b, 
1998) and loss of GABAergic (parvalbumin-positive) interneu-
rons in the anterior cingulate cortex (ACC) 6 weeks post-treatment 
(Abdul-Monim et al., 2007). These intervals are well within the 
time window in which we tested cognitive and social behavior. 
Interestingly in this context, a recent study in rats demonstrated 
that excitotoxic lesions of the ACC but not orbitofrontal cortex 
(OFC) reduced social interaction (and social memory) (Rudebeck 
et al., 2007) – mimicking the PCP-induced deﬁ  cit in our study. 
By contrast, there is compelling evidence that reversal learning 
is mediated by the OFC and not ACC (Schoenbaum et al., 2006), 
and preliminary evidence suggests that this subregion dissocia-
tion also holds for our mouse reversal task (while discrimination 
is not PFC-mediated) (Brigman et al. unpublished). On the basis 
of these various ﬁ  ndings, an heuristic model for further research 
is that the proﬁ  le of behavioral deﬁ  cits produced by subchronic 
PCP treatment in our study were produced by selective dysfunc-
tion of the mouse ACC.
In summary, current data investigated the effects of a   regimen 
of subchronic PCP treatment – previously proposed as a pharma-
cological model of the negative and cognitive/executive symptoms 
of schizophrenia (Jentsch and Roth, 1999; Jentsch and Taylor, 2001). 
Results suggested a partial deﬁ  cit in social behavior after subchronic 
PCP treatment and encourage further analysis of the potential util-
ity of this pharmacological model for studying the social withdrawal 
component of schizophrenia. It will also be of interest to test whether 
other negative symptoms of the disease (e.g., abnormal affect and 
anhedonia) are also modeled by this treatment. The current study 
did not observe deﬁ  cits in either discrimination or reversal learn-
ing in C57BL/6J mice after subchronic PCP treatment, despite evi-
dence that similar cognitive/executive processes are impaired in 
schizophrenics and PCP-treated rats. Further work will be needed 
to identify cognitive/executive measures that are sensitive to chronic 
PCP treatment in C57BL/6J, as well as alternative methods that 
produce discrimination and/or reversal impairment.
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